Victory Capital Management Inc. Sells 42,851 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Victory Capital Management Inc. lowered its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 50.5% in the third quarter, Holdings Channel.com reports. The institutional investor owned 41,934 shares of the medical equipment provider’s stock after selling 42,851 shares during the period. Victory Capital Management Inc.’s holdings in BioLife Solutions were worth $1,050,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in BLFS. 1620 Investment Advisors Inc. bought a new stake in shares of BioLife Solutions in the 2nd quarter valued at $35,000. Isthmus Partners LLC increased its position in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 42,265 shares in the last quarter. GAMMA Investing LLC increased its position in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of BioLife Solutions in the 2nd quarter valued at $122,000. Finally, Arizona State Retirement System bought a new position in BioLife Solutions during the 2nd quarter worth about $217,000. Institutional investors own 93.24% of the company’s stock.

Insider Transactions at BioLife Solutions

In other news, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total transaction of $239,000.00. Following the completion of the transaction, the executive vice president now directly owns 317,716 shares in the company, valued at $7,593,412.40. This represents a 3.05 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CRO Garrie Richardson sold 3,070 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the transaction, the executive now owns 114,773 shares of the company’s stock, valued at approximately $2,883,097.76. This represents a 2.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 69,644 shares of company stock worth $1,527,503 in the last three months. Insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Craig Hallum increased their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. HC Wainwright lowered their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a report on Monday, November 18th. TD Cowen increased their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Northland Securities increased their target price on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.50.

BioLife Solutions Trading Up 0.4 %

BioLife Solutions stock opened at $27.16 on Thursday. The firm has a 50-day moving average of $24.09 and a 200-day moving average of $23.14. BioLife Solutions, Inc. has a one year low of $11.91 and a one year high of $28.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -25.53 and a beta of 1.88.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.